Bolt Biotherapeutics (BOLT, Financial) experienced significant stock price growth, rising 5.08% to $0.670 per share on trading volume of 96,217 shares. Despite this increase, the company's latest financial report shows a challenging outlook with an operating revenue of $1.28 million, a net loss of $21.2 million, and an EPS of -$0.56, resulting in a negative P/E ratio of -0.38.
In the institutional ratings, all four involved institutions suggested holding the stock with none recommending buying or selling.
In the broader biotechnology industry, which saw a decline of 1.64%, other stocks like Ensysce Biosciences, Genprex, and Silexion Therapeutics showed significant gains. Genprex and Ensysce were particularly active with turnover rates of 5301.07% and 4765.12% respectively, and substantial price fluctuations with amplitudes of 189.27% and 101.99%.
Bolt Biotherapeutics is a clinical-stage immuno-oncology company focusing on tumor-targeted therapies leveraging innate and adaptive immune systems. Its proprietary Boltbody ISAC platform features tumor-targeting antibodies combined with immune-stimulating linkers, with candidate products including BDC-1001, BDC-3042, and Next-Gen ISAC.
